Antibiotic-Resistant Neisseria gonorrhoeae Spread Faster with More Treatment, Not More Sexual Partners

PLoS Pathog. 2016 May 19;12(5):e1005611. doi: 10.1371/journal.ppat.1005611. eCollection 2016 May.

Abstract

The sexually transmitted bacterium Neisseria gonorrhoeae has developed resistance to all antibiotic classes that have been used for treatment and strains resistant to multiple antibiotic classes have evolved. In many countries, there is only one antibiotic remaining for empirical N. gonorrhoeae treatment, and antibiotic management to counteract resistance spread is urgently needed. Understanding dynamics and drivers of resistance spread can provide an improved rationale for antibiotic management. In our study, we first used antibiotic resistance surveillance data to estimate the rates at which antibiotic-resistant N. gonorrhoeae spread in two host populations, heterosexual men (HetM) and men who have sex with men (MSM). We found higher rates of spread for MSM (0.86 to 2.38 y-1, mean doubling time: 6 months) compared to HetM (0.24 to 0.86 y-1, mean doubling time: 16 months). We then developed a dynamic transmission model to reproduce the observed dynamics of N. gonorrhoeae transmission in populations of heterosexual men and women (HMW) and MSM. We parameterized the model using sexual behavior data and calibrated it to N. gonorrhoeae prevalence and incidence data. In the model, antibiotic-resistant N. gonorrhoeae spread with a median rate of 0.88 y-1 in HMW and 3.12 y-1 in MSM. These rates correspond to median doubling times of 9 (HMW) and 3 (MSM) months. Assuming no fitness costs, the model shows the difference in the host population's treatment rate rather than the difference in the number of sexual partners explains the differential spread of resistance. As higher treatment rates result in faster spread of antibiotic resistance, treatment recommendations for N. gonorrhoeae should carefully balance prevention of infection and avoidance of resistance spread.

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Drug Resistance, Microbial / drug effects*
  • Female
  • Gonorrhea / drug therapy*
  • Gonorrhea / epidemiology*
  • Gonorrhea / transmission*
  • Humans
  • Incidence
  • Male
  • Models, Theoretical
  • Neisseria gonorrhoeae
  • Prevalence
  • Sexual Partners

Substances

  • Anti-Bacterial Agents

Grants and funding

SMF and CLA received funding from SwissTransMed, Platforms for Translational Research in Medicine (www.swisstransmed.ch, grant number 25/2013). SB is funded by a European Research Council Advanced Grant (erc.europa.eu, grant number PBDR 268540). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.